A feasibility study utilizing DNA-barcoded multiplex fluorescence IHC for immune profiling in the tumor microenvironment of bladder and lung samples

Background

- •Ultivue multiplex IHC technology uses antibody DNAbarcoding with signal amplification in tissues (**Fig. 1**)
- •Ultivue ULT30102 MTO assay includes 7 markers: CD3, CD8, CD68, GZMB, PD-L1, Ki67 and PanCK
- •The staining is automated with 2 Rounds of iterative staining & imaging (Table 1)

Aim

- •To establish a multiplex IHC method to study the tumor cellular microenvironment in biopsies
- •The long-term goal is to qualify and/or validate this multiplex IHC method for immunophenotyping (**Table 2**)

Methods

- •We tested the kit ULT30102 in 20 bladder and 20 lung whole tumor resections using the Bond RX automated stainer
- Digital images from Round 1 and Round 2 were acquired with the fluorescence scanner Vectra Polaris (additional images were acquired with Axio Slide Scanner)
- •Image processing and cell analysis was performed using HALO software (**Fig. 2**)
- Data analysis was completed with GraphPad and R

Results

- •Ultivue ULT30102 assay was able to detect CD3, CD8, CD68, GZMB, PD-L1, Ki67 and PanCK in bladder and lung samples
- •We classified tumors as Hot or Cold based on pathology and image analysis cellular data (**Fig. 3**)



Fluorescent probes MIX



The human biological samples were sourced ethically and their research use was in accord with the terms of the informed consents under an IRB/EC approved protocol."

Presented at Pathology Visions, 19 Oct 2020

Haydee Lara¹, Chifei Sun¹, David Krull¹, Bao Hoang², Fang Xie², Leslie Obert³, Daniela Ennulat³, Andrew Gehman⁴, Paul Noto⁵ & Vilma Decman¹. ¹IVIVT – Cellular Biomarkers, ²IVIVT – Bioimaging, ³IVIVT – Pathology, ⁴Biostatistics – Research Statistics, ⁵Oncology – EMU

Fig. 1. Ultivue DNA-barcoded multiplex IHC

Add all 7 antibodies in one step, DNAbarcode tag is unique

STEP 2 Amplify the DNA targets, all in one step



Table 2. List of potential immunophenotypes and classification segments for these studies CD3+/CD8+ All antibodies are applied in Normal tissue PanCK+/Ki-67+ staining STEP 1 (see Fig. 1). Tumor nest (epithelial) CD3+/CD8+/Ki-67+ fluorescent DNA Round • Tumor stroma PanCK+/PD-L1+etc probes are applied and imaged Round 2 DNA Then. Fig 3. Hot & cold classification of bladder tumors applied and are based on histopathology and HALO image analysis probes imaged. Tumor histopathologic classification is highlighted in the background: Hot (pink), Cold-ignored (blue), or Coldexcluded (green). Red (stroma) & green (tumor) dots represent image analysis data points for each sample. used image 10000.0-Staining Round 2 PDL1 Classification **D** 10000.0 **Tumor/stroma** bladder and 20 lung tumor samples PanCK trained to differentiate tumor vs tumor Immunostroma 1000 0-Region fluorescence intensity of the cells for Stroma Tumor their respective channels Path 14161 3 5 11 6 7 8 1215171819 2 4 1014161 3 5 11 6 7 8 1215171819 Sample Number Cold (Ign) Cold (Exc) to generate plots in Fig. 3

| Ultivue 7-plex Kit, ULT30102 | | |
|------------------------------|---------|---------|
| | Round 1 | Round 2 |
| FITC | CD8 | Ki67 |
| TRITC | CD68 | gzmb |
| Cy5 | PD-L1 | CD3 |
| Cy7 | | PanCK |

Table 1. Ultivue 7-plex kit markers are stained and imaged in 2 iterative rounds Fig 2. Image processing and cell analysis workflow Fused images were obtained for 20 Immunophenotyping was based on



- HALO-AI (Artificial Intelligence) was
- Immunophenotyping data was used



